Price
$29.00-18.19%Social Signal Score
Analyst Ratings
20 analysts52-week range
- Last close
- $29.00
- Off 52w high
- -53.8%
- 200-day average
- $27.54
- vs 200-day
- +5.3%
Revenue
$753.21M+4072.35%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Andrew Dudum
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 2,442
- Beta
- 2.41
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 1.59
Financials
Revenue
$753.21M+4072.4%Net Income
$-86.29MEBITDA
$-63.16MFree Cash Flow
$-55.38MEPS (diluted)
$-0.37Shares Outstanding (diluted)
231.75M+505.4%Operating Expenses
$427.61MCash & Debt
$841.05MReturn of Capital
$23.07MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.35B | $128.37M | $0.57 |
| 2024 | $1.48B | $126.04M | $0.58 |
| 2023 | $872.00M | $-23.55M | $-0.11 |
| 2022 | $526.92M | $-65.68M | $-0.32 |
| 2021 | $271.88M | $-107.66M | $-0.58 |
| 2020 | $148.76M | $-18.11M | $-0.51 |
| 2019 | $82.56M | $-72.06M | $-2.07 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.84
- Implied price
- $47.79
- Return from $29.00
- 10.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $23.76 — -18.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 39 | 48 | 57 | 66 | 75 |
|---|---|---|---|---|---|
| -2.0% | -7.1% | -3.1% | 0.3% | 3.3% | 5.9% |
| 3.0% | -2.3% | 1.8% | 5.4% | 8.5% | 11.3% |
| 8.0% | 2.4% | 6.8% | 10.5% | 13.8% | 16.7% |
| 13.0% | 7.2% | 11.7% | 15.6% | 19.1% | 22.1% |
| 18.0% | 11.9% | 16.7% | 20.7% | 24.3% | 27.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-18.01%Social Signal Score
Mentions (92)
- Newszacks.com·22h ago·Neutral
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
View source ↗ - News (Marketaux)economictimes.indiatimes.com·3d ago·Positive
Robinhood stock tokens turbocharge a new era of meme trading He bought a memecoin paired with Him[+326 characters]
View source ↗ - Newszacks.com·4d ago·Neutral
Hims & Hers Health, Inc. (HIMS) Stock Slides as Market Rises: Facts to Know Before You Trade In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $29.3, marking a -1.64% move from the previous day.
View source ↗ - News (RSS)seekingalpha·5d ago·Neutral
Hims & Hers Goes Global - Renewed Growth Prospects With Margin Risks
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Hims & Hers: U.S. Revenue Reacceleration Is Reassuring, And Valuation Compression Is Compelling (Upgrade) Hims & Hers is upgraded to a buy as revenue growth reaccelerates and valuation compresses, offering a compelling entry point. HIMS targets $6.5B+ revenue and $1.3B+ adjusted EBITDA by 2030, implying a >20% revenue and ~44% EBITDA CAGR from 2026-2030. Recent Q2 results showed 38% y/y revenue growth (31% organic), a strong U.S. rebound, and nearly 3M subscribers, despite margin pressure.
View source ↗ - Newszacks.com·12d ago·Neutral
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $28.39, moving 6.7% from the previous trading session.
View source ↗ - 4chan /biz/biz·13d ago·Positive
Oh and if anyone is wondering why HIMS dropped 5% in 5 minutes, thats because i fullported into calls.
View source ↗ - Newsprnewswire.com·14d ago·Negative
Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit BENSALEM TOWNSHIP, Pa., Sept. 21, 2026 /PRNewswire/ -- The Law Offices of Howard G.
View source ↗ - Newszacks.com·14d ago·Neutral
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
View source ↗ - News (RSS)fool·16d ago·Negative
Hims & Hers Chief Legal Officer Soleil Boughton Sells 6,236 Shares The insider still retains significant holdings, valued at $8.5 million, despite the sale.
View source ↗ - Newsfool.com·16d ago·Negative
Hims & Hers Chief Legal Officer Soleil Boughton Sells 6,236 Shares The transaction involved shares equal to 2% of the stake held before the filing. The executive retains direct ownership of approximately 304,000 shares following the completion of the sale.
View source ↗ - Newsprnewswire.com·17d ago·Negative
Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit LOS ANGELES, Sept. 18, 2026 /PRNewswire/ -- The Law Offices of Howard G.
View source ↗ - Newsfool.com·19d ago·Positive
Is Hims & Hers Stock a Buy Right Now in September? The healthcare industry is ripe for disruptions.
View source ↗ - Newszacks.com·20d ago·Neutral
Hims & Hers Health, Inc. (HIMS) Falls More Steeply Than Broader Market: What Investors Need to Know In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $27.93, indicating a -3.07% shift from the previous trading day.
View source ↗ - News (RSS)seekingalpha·21d ago·Neutral
Hims & Hers: Pivot To Branded Distribution Is Eating The Margins Alive
View source ↗ - Newsschaeffersresearch.com·21d ago·Negative
HIMS Bulls Should Heed This Historic Chart Signal Drugmaker Hims & Hers Health Inc (NYSE:HIMS) stock is moving 6.6% higher to trade at $29.34 this afternoon.
View source ↗ - Newsfool.com·23d ago·Neutral
I'm Calling It: Hims & Hers Health Will Soar 56% by the End of 2026 Hims & Hers Health is expected to grow revenue sharply in 2027. Subscriber growth and rising revenue per subscriber continue to strengthen the company's operational momentum.
View source ↗ - News (Marketaux)gurufocus.com·24d ago·Positive
HIMS Assumes Neutral Rating by JP Morgan -- Price Target Announced at $32 Hims & Hers Health[+211 characters]
View source ↗ - News (RSS)investing·24d ago·Neutral
JPMorgan cautious on Hims & Hers on GLP-1 transition risk
View source ↗ - Newszacks.com·26d ago·Neutral
Why Is Hims & Hers Health (HIMS) Down 7.7% Since Last Earnings Report? Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·27d ago·Positive
Hims & Hers Health, Inc. (HIMS) Gains As Market Dips: What You Should Know The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $28.17, representing a +1.66% change from its previous close.
View source ↗ - Newszacks.com·27d ago·Neutral
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
View source ↗ - Newsfeeds.newsfilecorp.com·28d ago·Neutral
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm New York, New York--(Newsfile Corp. - September 7, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
View source ↗ - News (RSS)decrypt·31d ago·Negative
Crypto Traders Are Pairing Meme Coins With Stocks on Robinhood—And It's Working (Sort Of) A meme coin called BONER cornered half of Hims & Hers Health's tokenized shares on Robinhood's new blockchain. It started a new trend that's spreading fast.
View source ↗ - Newsbusinesswire.com·33d ago·Negative
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $HIMS--HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law.
View source ↗ - Newszacks.com·33d ago·Negative
HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss HIMS raised its 2026 revenue outlook after Q2 sales jumped 38.2%, but margin contraction and an $86.3 million net loss highlighted growth costs.
View source ↗ - Newszacks.com·33d ago·Negative
Reasons to Retain Hims & Hers Stock in Your Portfolio for Now HIMS has entered the second half of 2026 with weight-loss, international and AI momentum, but margin pressure and FDA uncertainty remain.
View source ↗ - Newsbusinesswire.com·34d ago·Negative
Stockholder Alert: Robbins LLP Informs Investors of the Hims & Hers Health, Inc. Class Action SAN DIEGO--(BUSINESS WIRE)---- $HIMS #HIMS--The complaint alleges that Hims shared customers' protected health information with advertisers and engaged in other deceptive advertising practices.
View source ↗ - Newsproactiveinvestors.com·34d ago·Negative
Hims & Hers falls after FDA crackdown on unapproved weight-loss drugs Hims & Hers Health (NYSE:HIMS) shares fell 3.2% after the FDA warned telehealth companies and compounding pharmacies over unapproved weight-loss drugs, including versions of semaglutide, tirzepatide and retatrutide. The agency said retatrutide and cagrilintide cannot legally be used in compounding and that it has already warned companies marketing unapproved retatrutide directly to consumers.
View source ↗ - News (RSS)yahoo·35d ago·Neutral
Hims & Hers’ Australia Expansion Adds Growth, But Execution Will Be Key
View source ↗ - Newsbusinesswire.com·35d ago·Neutral
Hims Enters Australia, Marking First Expansion into the Asia-Pacific Market SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced it is now serving customers in Australia, marking the company's first-ever presence in the Asia-Pacific market. The entry follows Hims & Hers' acquisition of Eucalyptus earlier this year and begins with the rebrand of Pilot, Eucalyptus' men's health platform, marking the first Eucalyptus…
View source ↗ - Newsbusinesswire.com·35d ago·Neutral
Hims Arrives in Australia, Bringing Personalised Care for Men Nationwide SYDNEY--(BUSINESS WIRE)--Hims & Hers, the leading global health and wellness platform, today announced it is officially launching the Hims brand in Australia and bringing its personalised care platform to men nationwide. The entry follows Hims & Hers' acquisition of Eucalyptus earlier this year and begins with the rebrand of Pilot, Eucalyptus' men's health platform. Effective today, Pilot becomes Hims. Patients will maintai
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (NYSE: HIMS) PHILADELPHIA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC announces an investigation into the Board of Directors of Hims & Hers Health, Inc. (NYSE: HIMS) (“Hims & Hers” or the “Company”) for potential breaches of fiduciary duties owed to the Company and its shareholders. The investigation is focused on whether the Company improperly shared…
View source ↗ - Newsseekingalpha.com·36d ago·Positive
…ms & Hers Health is building a vertically integrated consumer-health distribution platform, with value driven by its scalable engine rather than individual products. HIMS demonstrates accelerating growth, with multiple product lines surpassing $100M ARR and rapid vertical launches, supporting a strong buy rating and a $111 price target for 2026. Q2 results showed robust revenue growth (38%) and strong Q3 guidance (47-50%), despite margin compression from branded weight-loss and international exp…
View source ↗ - 4chan /biz/biz·36d ago·Positive
…o a new meta of memecoins with taxes that accumulate the tokenized stock they're paired with to try to gain a seat on the board of the company itself. AI/NVDA, BONER/HIMS, and CINEMA/AMC are the most interesting pairs I've seen so far, though there are a lot of promising ones out there.
View source ↗ - News (RSS)yahoo·38d ago·Neutral
Hims & Hers (HIMS) CEO Says the FTC Doesn’t Understand His Own Company
View source ↗ - Newsfool.com·38d ago·Positive
After Doubling in Six Months, Is it Too Late to Buy Hims & Hers Stock? The share price is up over 100% in the previous six months.
View source ↗ - Newsnewsfilecorp.com·38d ago·Negative
Kaplan Fox is Investigating Hims & Hers Health, Inc. (HIMS) for Potential Violations of the Federal Securities Laws New York, New York--(Newsfile Corp. - August 28, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Hims & Hers investor and have suffered losses, or if you have information that could assist i…
View source ↗ - News (RSS)seekingalpha·39d ago·Neutral
Hims & Hers Is Growing Into Something Much Bigger
View source ↗ - Newsseekingalpha.com·39d ago·Neutral
Hims & Hers Is Growing Into Something Much Bigger Hims & Hers approaches 3 million subscribers as U.S. growth reaccelerates and international markets emerge as a meaningful second growth engine. International revenue reached $131 million, while testosterone is approaching Hims' sixth U.S. specialty above a $100 million annual run rate. Gross margin fell to 64%, while Q2 free cash flow reached negative $68 million, making operating leverage the critical next test.
View source ↗ - Newsnewsfilecorp.com·40d ago·Negative
Kaplan Fox & Kilsheimer LLP is Investigating Hims & Hers Health, Inc. (HIMS) for Possible Securities Law Violations New York, New York--(Newsfile Corp. - August 26, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Hims & Hers investor and have suffered losses, or if you have information that could assist i…
View source ↗ - Newsnewsfilecorp.com·40d ago·Neutral
Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (HIMS) Philadelphia, Pennsylvania--(Newsfile Corp. - August 26, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into the Board of Directors of Hims & Hers Health, Inc. (NYSE: HIMS) ("Hims & Hers" or the "Company") for potential breaches of fiduciary duties owed to the Company and its shareholders. The investigation is focused on whether the Company improp…
View source ↗ - Newsglobenewswire.com·41d ago·Negative
Hims & Hers Health, Inc. Investigated by the Portnoy Law Firm LOS ANGELES, Aug. 25, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Hims & Hers Health, Inc., (“Hims" or the "Company") (NYSE: HIMS) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
View source ↗ - Newsglobenewswire.com·41d ago·Negative
Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation BENSALEM, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) investors concerning the Company's possible violations of federal securities laws.
View source ↗ - Newsglobenewswire.com·42d ago·Negative
Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES, Aug. 24, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) on behalf of investors concerning the Company's possible violations of federal securities laws.
View source ↗ - Newsnewsfilecorp.com·42d ago·Negative
Kaplan Fox Reminds Hims & Hers Health, Inc. (HIMS) Investors of an Investigation into Potential Securities Law Violations New York, New York--(Newsfile Corp. - August 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Hims & Hers investor and have suffered losses, or if you have information that could as…
View source ↗ - News (RSS)seekingalpha·45d ago·Negative
Hims & Hers Health facing penalties from Visa for credit card disputes - report
View source ↗ - News (RSS)investing·45d ago·Neutral
Hims & Hers faces Visa penalties over dispute surge - Bloomberg
View source ↗ - Newsnewsfilecorp.com·45d ago·Negative
Kaplan Fox & Kilsheimer LLP Alerts Investors of Hims & Hers Health, Inc. (HIMS) to an Investigation of Potential Securities Law Violations New York, New York--(Newsfile Corp. - August 21, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Hims & Hers investor and have suffered losses, or if you have informat…
View source ↗ - Newszacks.com·45d ago·Neutral
HIMS Stock More Than Doubled in 6 Months: What's Driving the Rally? Hims & Hers' rally is fueled by branded weight-loss growth, international expansion, AI efficiencies and a broader specialty portfolio.
View source ↗ - News (RSS)yahoo·46d ago·Negative
Hims & Hers Health (HIMS) & Novo Nordisk A/S (NVO): Two Weight-Loss Pill Players Just Got Punished for Growing Fast
View source ↗ - Newsnewsfilecorp.com·47d ago·Negative
Kaplan Fox is Investigating Hims & Hers Health, Inc. (HIMS) on Behalf of Investors for Potential Securities Law Violations New York, New York--(Newsfile Corp. - August 19, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Hims & Hers investor and have suffered losses, or if you have information that could a…
View source ↗ - Newsseekingalpha.com·47d ago·Neutral
Hims & Hers: Buying The Margin Dip Hims & Hers Health (HIMS) is rated a buy at current levels, driven by robust international expansion and product innovation. International revenue surged over 17-fold YoY to $131M, with Eucalyptus acquisition and new markets fueling growth and future $600M+ 2026 target. AI investment aims to reduce customer-support costs and improve retention, with payback expected in 12–18 months as in-house capabilities scale.
View source ↗ - News (RSS)fool·47d ago·Neutral
Hims & Hers' Chief Accounting Officer Is Leaving. Here's What Her Latest Insider Filing Shows This filing notes that shares were withheld automatically to cover tax obligations from quarterly RSU vesting.
View source ↗ - News (RSS)fool·47d ago·Positive
An Insider at Hims & Hers Just Filed. Here's What It Says About Buying the Dip Soleil Boughton retains roughly 339,000 shares and additional derivative securities.
View source ↗ - Newsnewsfilecorp.com·47d ago·Neutral
Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (HIMS) Philadelphia, Pennsylvania--(Newsfile Corp. - August 19, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into the Board of Directors of Hims & Hers Health, Inc. (NYSE: HIMS) ("Hims & Hers" or the "Company") for potential breaches of fiduciary duties owed to the Company and its shareholders. The investigation is focused on whether the Company improp…
View source ↗ - News (RSS)fool·47d ago·Neutral
Hims & Hers' Policy Chief Just Filed an Insider Transaction. Here's What It Means. This non-discretionary sale was tied to RSU tax withholding; the insider retains 65,734 direct shares and 428,000 derivative securities, per the filing.
View source ↗ - News (RSS)yahoo·47d ago·Positive
Hims & Hers' CEO Just Disposed of 78,859 Shares. Here's What Long-Term Investors Should Know.
View source ↗ - News (RSS)fool·47d ago·Positive
An Insider at Hims & Hers Disposed of Over $3 Million in Stock. Here's What Long-Term Investors Should Know The disposition comes as HIMS stock has declined 38% over the past 12 months.
View source ↗ - News (RSS)fool·47d ago·Negative
The CTO of Hims & Hers Just Gave Up Nearly $2.7 Million in Stock. Here's What It Actually Means This non-discretionary tax withholding reduced the CTO of Hims' direct holdings, though he retains roughly 194,000 shares and roughly 2 million derivative securities subject to multi-year vesting.
View source ↗ - News (RSS)fool·47d ago·Neutral
Hims & Hers' CEO Just Disposed of 78,859 Shares. Here's What Long-Term Investors Should Know. Stock-based compensation vesting triggered mandatory tax withholding, but Dudum retains about 9.7 million shares worth $272 million.
View source ↗ - Newsfool.com·48d ago·Neutral
Hims & Hers' Chief Accounting Officer Is Leaving. Here's What Her Latest Insider Filing Shows The disposition involved 6,490 shares worth about $183,000 at a price of $28.15 per share on August 14. All shares were withheld by the issuer to cover tax obligations following the quarterly vesting of restricted stock units (RSUs).
View source ↗ - Newsfool.com·48d ago·Positive
An Insider at Hims & Hers Just Filed. Here's What It Says About Buying the Dip The disposition involved 21,500 shares valued at about $605,000 as of the August 14 transaction date. Soleil Boughton maintains direct ownership of 339,000 shares and holds additional derivative securities following the liquidation.
View source ↗ - Newsfool.com·48d ago·Positive
What Long-Term Investors Should Know About This Hims Insider Filing This disposition of 47,702 shares was executed at $28.15 per share for a total transaction value of $1.3 million. This activity was non-discretionary, as shares were withheld to satisfy tax liabilities associated with the quarterly vesting of restricted stock units.
View source ↗ - Newsfool.com·48d ago·Neutral
A Hims & Hers Insider Disposed of Stock as the Company Pushes Into Testosterone and Peptides. Here's What to Know The disposition involved 10,201 shares for an estimated value of $287,000 on the August 14 transaction date. The transaction was entirely direct, leaving the officer with 197,847 shares in direct ownership.
View source ↗ - Newsfool.com·48d ago·Neutral
Hims & Hers' Policy Chief Just Filed an Insider Transaction. Here's What It Means. The disposition involved 16,147 shares for a total transaction value of about $455,000 at $28.15 per share. This was a non-discretionary transaction executed to satisfy tax withholding obligations following the vesting of restricted stock units.
View source ↗ - Newsfool.com·48d ago·Positive
An Insider at Hims & Hers Disposed of Over $3 Million in Stock. Here's What Long-Term Investors Should Know The total transaction value reached $3.2 million based on a weighted average execution price of $31.92 per share. The activity involved the exercise of 101,208 stock options and the withholding of 36,437 shares by the company to satisfy tax obligations.
View source ↗ - Newsfool.com·48d ago·Neutral
The CTO of Hims & Hers Just Gave Up Nearly $2.7 Million in Stock. Here's What It Actually Means The transaction involved the disposal of 95,798 shares with an estimated value of about $2.7 million based on the transaction date market close. The transaction was non-discretionary, executed to cover tax obligations related to the vesting and settlement of restricted stock units (RSUs).
View source ↗ - Newsfool.com·48d ago·Neutral
Hims & Hers' CEO Just Disposed of 78,859 Shares. Here's What Long-Term Investors Should Know. The transaction involved 78,859 shares with a total value of $2.2 million as of August 14. This non-discretionary disposition reduced the CEO's direct holdings by 7% while his total equity position remains at about 9.7 million shares.
View source ↗ - News (Finnhub)CNBC·48d ago·Neutral
Hims & Hers CEO says FTC lawsuit misunderstands how the company works Hims & Hers CEO Andrew Dudum spoke to CNBC about the FTC's lawsuit against the company, compounded GLP-1 drugs and AI.
View source ↗ - Newsyoutube.com·48d ago·Neutral
Watch CNBC's full interview with Hims & Hers CEO Andrew Dudum In an exclusive interview, Hims & Hers CEO Andrew Dudum sits down with Squawk Box Co-Anchor Andrew Ross Sorkin and shares his perspective on how AI can transform healthcare, the company's transition from compound to brand name GLP-1s, and his vision to bring down the cost of healthcare.
View source ↗ - News (RSS)yahoo·49d ago·Positive
Hims (HIMS) Q2 2026 Earnings Call Transcript
View source ↗ - News (RSS)seekingalpha·50d ago·Neutral
Notable healthcare headlines for the week: Eli Lilly, Hims & Hers Health, and Merck in focus
View source ↗ - Newsnewsfilecorp.com·52d ago·Negative
Kaplan Fox & Kilsheimer LLP Announces an Investigation into Hims & Hers Health, Inc. (HIMS) for Possible Securities Law Violations New York, New York--(Newsfile Corp. - August 14, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Hims & Hers investor and have suffered losses, or if you have information that…
View source ↗ - Newsseekingalpha.com·52d ago·Neutral
Hims & Hers Health's Next Act: Making Its Own Drugs Again I'm maintaining my buy on Hims & Hers Health, and the reasoning has moved past the branded GLP-1 transition that drove my May upgrade. 2Q revenue grew 38% to $753.2 million and management raised the full-year outlook to $3.1–$3.3 billion, while gross margin fell six points sequentially to 64%. HIMS is now a distribution layer for branded weight-loss drugs, a business that buys revenue with margin, and the EBITDA guide shows the bill.
View source ↗ - Newsglobenewswire.com·53d ago·Negative
Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Continuing Securities Fraud Investigation BENSALEM, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) investors concerning the Company's possible violations of federal securities laws.
View source ↗ - Newsreuters.com·54d ago·Neutral
As Hims prepares for peptides launch, Wall Street cautious on prospects this year Hims & Hers Health plans to offer some legally available peptides in 2026, but investors and analysts who spoke to Reuters after the telehealth company's quarterly results this week said sales for that offering are unlikely to drive revenue growth this year.
View source ↗ - Newsglobenewswire.com·54d ago·Negative
Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES, Aug. 12, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) on behalf of investors concerning the Company's possible violations of federal securities laws.
View source ↗ - Newsprnewswire.com·54d ago·Neutral
Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (NYSE: HIMS) PHILADELPHIA, Aug. 12, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into the Board of Directors of Hims & Hers Health, Inc. (NYSE: HIMS) ("Hims & Hers" or the "Company") for potential breaches of fiduciary duties owed to the Company and its shareholders. The investigation is focused on whether the Company improperly shared pri
View source ↗ - Newsseekingalpha.com·55d ago·Negative
Hims & Hers: The Guidance Raise Doesn't Fix The Margin Problem Hims & Hers Health delivered strong Q2 2026 revenue growth but suffered margin compression and negative free cash flow. I rate HIMS a Sell, as the raised revenue guidance is offset by declining gross margins and a stagnant adjusted EBITDA outlook. The shift to branded GLP-1 weight-loss drugs and international expansion are driving higher costs and complicating the profitability story.
View source ↗ - Newszacks.com·55d ago·Negative
Hims & Hers Stock Plunges Post Q2 Earnings Miss, Gross Margin Down HIMS posts a wider-than-expected loss and weaker gross margin in second-quarter 2026 despite strong revenue growth and a raised full-year outlook.
View source ↗ - Newsproactiveinvestors.com·55d ago·Neutral
Hims & Hers Q2 revenue beat offset by wider-than-expected loss Hims & Hers Health (NYSE:HIMS) delivered mixed second-quarter results, with revenue beating Wall Street expectations while its quarterly loss came in wider than analysts had forecast as the company incurred restructuring charges tied to its shift toward branded GLP-1 weight-loss options. Revenue for the quarter ended June 30 rose 38% year over year to $753.2 million, topping the roughly $699 million analysts had expected.
View source ↗ - Newszacks.com·55d ago·Neutral
HIMS Q2 Earnings Call Focuses on AI and Global Expansion Hims & Hers raises its 2026 revenue outlook as AI boosts engagement, specialty care expands and Eucalyptus extends its international reach despite margin pressure.
View source ↗ - Newsnewsfilecorp.com·55d ago·Negative
Kaplan Fox Alerts Hims & Hers Health, Inc. (HIMS) Investors to an Investigation of Potential Securities Law Violations New York, New York--(Newsfile Corp. - August 11, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Hims & Hers investor and have suffered losses, or if you have information that could assis
View source ↗ - Newsschaeffersresearch.com·55d ago·Negative
Hims & Hers Health Slides on Wider-Than-Expected Q2 Loss Hims & Hers Health (NYSE:HIMS) shares were last seen down 7% to trade at $29.54.
View source ↗ - Newsreuters.com·56d ago·Positive
Hims & Hers shares slide as costly weight-loss push squeezes margins Hims & Hers Health's shares fell nearly 7% in premarket trading on Tuesday, as concerns over shrinking profit margins overshadowed strong subscriber growth and a raised annual revenue forecast.
View source ↗ - Newsinvezz.com·56d ago·Negative
Hims & Hers stock drops 7% despite higher guidance: what went wrong? Shares of Hims & Hers Health fell more than 7% in premarket trading on Tuesday after the telehealth company reported a wider-than-expected second-quarter loss, as investments in branded GLP-1 weight-loss treatments and international expansion weighed on profitability. The company reported a net loss of 37 cents per share for the quarter, compared with analysts' expectations for a loss of 1 cent per share, according to LSEG data
View source ↗ - Newsseekingalpha.com·56d ago·Positive
Hims & Hers Health, Inc. (HIMS) Q2 2026 Earnings Call Transcript Hims & Hers Health, Inc. (HIMS) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·56d ago·Neutral
Hims & Hers Health Q2 Earnings Call Highlights Hims & Hers Health NYSE: HIMS reported second-quarter 2026 revenue of more than $753 million, up nearly 40% from a year earlier, as the telehealth company added 300,000 net new subscribers and ended the period with nearly 3 million subscribers globally.
View source ↗ - News (RSS)investing.com·56d ago·Neutral
After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
View source ↗ - Newszacks.com·56d ago·Negative
Hims & Hers Health, Inc. (HIMS) Reports Q2 Loss, Tops Revenue Estimates Hims & Hers Health, Inc. (HIMS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.17 per share a year ago.
View source ↗ - Newsbenzinga.com·56d ago·Neutral
Hims & Hers Shares Drop After Mixed Q2 Earnings — Details Hims & Hers Health Inc. (NYSE:HIMS) posted its second-quarter results after Monday's closing bell, missing analysts' EPS estimate, but beating on revenue. Here's a look at the details inside the report.
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $0.07 per share
Typical surprise -5.6% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.37 vs $-0.05miss
- Mon, May 11$-0.40 vs $0.03miss
- Mon, Feb 23$0.07 vs $0.02beat
- Mon, Nov 3$0.06 vs $0.09miss
- Mon, Aug 4$0.17 vs $0.18miss
- Mon, May 5$0.20 vs $0.12beat
Estimates and results for HIMS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HIMS officers and directors.
- Bought
- —
- Sold
- $7.7m
0 trades
17 trades
- Okupe Oluyemisold
- Boughton Soleilsold
- Okupe Oluyemisold
- Okupe Oluyemisold
- Boughton Soleilsold
- Chi Michaelsold
- Elshenawy Mohamedsold
- Boughton Soleilsold
83 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Lisa C. McClainhouse · MI09 · disclosed Sep 15, 2025 (42d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.